Cancer Therapy Resistance
Cancer Therapy Resistance - Related Videos
08:45
Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
0 Views •
Cited by 8 •
2012
Use of Cerenkov Luminescence Imaging (CLI) for monitoring preclinical cancer treatment is described here. This method takes advantage of Cerenkov Radiation (CR) and optical imaging (OI) to visualize radiolabeled probes and thus provides an alternative to PET in preclinical therapeutic monitoring and drug screening.
02:49
Cancer Therapies
0 Views •
2023
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients. However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49
Cancer Therapies
0 Views •
2021
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients. However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56
Treatment Resistent Cancers
0 Views •
2023
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56
Treatment Resistant Cancers
0 Views •
2021
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
FAQs
Resistance may exist in a subset of tumor cells before therapy begins. Treatment then inhibits susceptible cells, allowing resistant clones to survive and expand. In other cases, cancer cells develop adaptive changes during treatment that support continued survival. Distinguishing preexisting resistance from treatment-emergent resistance helps researchers interpret relapse and study how tumors change over time.
Genetic changes can alter cellular functions in ways that reduce treatment effectiveness, while epigenetic changes modify gene activity without necessarily changing the underlying DNA sequence. Both processes can help cancer cells maintain survival programs under treatment pressure. Their contribution is important because resistance may reflect both stable inherited traits and reversible changes in tumor-cell behavior.
Several cellular processes can reduce treatment impact through different routes. Increased DNA repair may correct damage that would otherwise limit survival, whereas reduced drug uptake or increased drug efflux can lower intracellular exposure. Altered cell-death signaling may prevent treated cells from undergoing death. These mechanisms can operate separately or together within the same tumor.
Researchers examine how treatment changes the composition and behavior of tumor-cell populations over time. If susceptible cells decline while resistant clones persist or expand, that pattern provides evidence of tumor evolution under treatment pressure. Studying these shifts can help connect resistance mechanisms with disease progression and support the search for biomarkers that predict treatment response.
Combination therapies are considered because resistance can arise through more than one route, including altered DNA repair, drug transport, cell-death signaling, or microenvironmental protection. Addressing multiple vulnerabilities may reduce the opportunity for resistant cells to persist. In cancer biology, this strategy is investigated as a way to delay relapse rather than relying on a single treatment effect.
Predictive biomarkers can help identify tumor features associated with likely treatment response or resistance. Monitoring disease evolution can then reveal whether resistant populations are emerging or expanding during therapy. Together, these approaches support more personalized treatment decisions and help researchers evaluate whether an intervention is delaying relapse or whether resistance is becoming dominant.